Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent
Tian-ying Xu,Peng Wang,Jia-sheng Tian,Sheng-li Qing,Shu-na Wang,Ya-hui Huang,Jin-yi Xu,Ding-feng Su,Jian-guo Liu,Chao-yu Miao
DOI: https://doi.org/10.1038/s41401-021-00636-1
IF: 7.169
2021-03-29
Acta Pharmacologica Sinica
Abstract:Hypertension is a serious public health problem worldwide. MT-1207, chemically named 3-(4-(4-(1H-benzotriazole-1-yl)butyl)piperazine-1-yl) benzisothiazole hydrochloride, is a new chemical entity that has entered into clinical trial as antihypertensive agent in China. In this paper we report the pharmacological profile of MT-1207 regarding its acute, subacute, and long-term effects on hypertensive animal models, and its actions on isolated organs in vitro as well as its molecular targets. Blood pressure (BP) was measured in conscious animals; amlodipine was taken as a positive control drug. We showed that both single dose of MT-1207 (1.25−20 mg/kg, ig) in spontaneously hypertensive rats (SHR) and MT-1207 (0.25−6 mg/kg, ig) in two-kidney one-clip (2K1C) dogs dose-dependently decreased BP. MT-1207 quickly decreased BP within 5 min after administration; the hypotensive effect lasted for 8 and 12 h, respectively, in SHR and 2K1C dogs without reflex increase in heart rate. Multiple doses of MT-1207 (5 mg · kg<sup>−1</sup> · d<sup>−1</sup> in SHR; 2 mg · kg<sup>−1</sup> · d<sup>−1</sup> in 2K1C dogs, for 7 days) significantly decreased BP, slightly reduced heart rate, and both of them recovered after withdrawal. Long-term administration of MT-1207 (10 mg · kg<sup>−1</sup> · d<sup>−1</sup> for 4 months or more time) produced a stable BP reduction, improved baroreflex sensitivity, reduced renal and cardiovascular damage in SHR, and delayed stroke occurrence and death in stroke-prone SHR. In isolated rat aortic rings precontracted by adrenaline, KCl, noradrenaline or 5-hydroxytryptamine (5-HT), MT-1207 (10<sup>−9</sup>–10<sup>−4</sup> M) caused concentration-dependent relaxation. In a panel of enzyme activity or radioligand binding assays of 87 molecular targets, MT-1207 potently inhibited adrenergic α<sub>1A</sub>, α<sub>1B</sub>, α<sub>1D</sub>, and 5-HT<sub>2A</sub> receptors with <i>K</i><sub>i</sub> < 1 nM. The antagonism of MT-1207 against these receptors was confirmed in isolated rabbit arteries. We conclude that MT-1207 is a novel and promising single-molecule multitarget agent for hypertension treatment to reduce hypertensive organ damage and stroke mortality.
pharmacology & pharmacy,chemistry, multidisciplinary